Does Medicare cover GLP-1 for weight loss?

Currently, no. Medicare Part D explicitly excludes anti-obesity medications. The Treat and Reduce Obesity Act, if passed, would change this. Medicare does cover GLP-1 medications (Ozempic, Mounjaro) when prescribed for type 2 diabetes.

What if my insurance denies GLP-1 coverage?

Appeal the denial. Many initial denials are reversed on appeal, especially with strong documentation from your doctor. Your prescriber's office can submit a letter of medical necessity including your BMI, comorbidities, and failed prior interventions. Some insurance plans have external review processes if internal appeals fail.

Are compounded semaglutide and tirzepatide safe?

Quality varies significantly. Compounded medications from reputable 503B outsourcing facilities (FDA-registered) are generally safer than those from unregulated sources. However, compounded versions lack the quality assurance of FDA-approved products. The FDA has warned about some compounded semaglutide products containing incorrect doses or contaminants.

How much do GLP-1 medications cost per month?

List price: $1,000-1,350/month. With commercial insurance and manufacturer savings: potentially $25-150/month. Without insurance: full list price unless you qualify for patient assistance programs or use compounding pharmacies ($200-500/month). The effective price varies enormously by individual situation.

GLP-1 Cost and Insurance: How to Actually Afford Weight Loss Medication

The biggest barrier to GLP-1 treatment isn't side effects or supply — it's cost. Without insurance, semaglutide (Ozempic/Wegovy) runs approximately $1,000-1,350 per month. Tirzepatide (Mounjaro/Zepbound) costs $1,000-1,200 per month. These prices put life-changing medication out of reach for millions. But the actual amount you pay varies enormously based on your insurance, the specific formulation, your diagnosis, and whether you access manufacturer programs.

Insurance Coverage: The Diabetes vs Obesity Split

Insurance coverage differs dramatically based on indication:

For type 2 diabetes: Most commercial insurance plans and Medicare Part D cover Ozempic and Mounjaro (though copays and prior authorization requirements vary). These are established diabetes medications with strong formulary positioning.

For weight management: Coverage is far less consistent. Many commercial plans cover Wegovy or Zepbound, but many don't — and they may require prior authorization, step therapy (trying cheaper medications first), or documented weight-related comorbidities. Medicare currently does not cover anti-obesity medications (the Treat and Reduce Obesity Act would change this if passed). Medicaid coverage varies by state.

How to Check Your Coverage

Call the number on the back of your insurance card and ask specifically: "Does my plan cover [medication name] for [your indication]?" Ask about: prior authorization requirements, step therapy requirements, preferred pharmacy, copay/coinsurance amounts, and quantity limits. Get the formulary tier — Tier 1-2 means lower copay; Tier 3+ means higher, sometimes significantly.

Manufacturer Savings Programs

Novo Nordisk (Ozempic/Wegovy): Offers savings cards that can reduce copays to $25/month for commercially insured patients. Eligibility requirements apply. These programs typically don't cover patients on government insurance (Medicare, Medicaid, Tricare).

Eli Lilly (Mounjaro/Zepbound): Offers savings programs with similar structures. The Lilly program has at times offered particularly aggressive discounts during launch periods.

These programs change frequently — check manufacturer websites directly for current offers. Your prescriber's office often has the latest information.

Prior Authorization Tips

Prior authorization (PA) is your insurer's way of gatekeeping expensive medications. To improve approval chances: document BMI and weight-related comorbidities (hypertension, type 2 diabetes, sleep apnea, dyslipidemia). Show that lifestyle modifications have been attempted. Have your doctor write a strong letter of medical necessity. If denied, appeal — many initial denials are reversed on appeal, and your doctor's office can help with this process.

Compounding Pharmacies

During FDA-declared shortages of semaglutide and tirzepatide, compounding pharmacies could legally produce versions at lower cost (typically $200-500/month). Compounded medications are not FDA-approved and quality varies by pharmacy. If the shortage designation is lifted, compounded versions become legally questionable. This space is evolving rapidly — check current FDA status before pursuing this route.

Other Cost-Reduction Strategies

Prescription discount programs: GoodRx and similar platforms may reduce cash prices slightly but typically don't make GLP-1s affordable without insurance.

Clinical trials: Participating in trials provides free medication and monitoring. ClinicalTrials.gov lists ongoing studies, particularly for newer agents like retatrutide.

Patient assistance programs: Both Novo Nordisk and Eli Lilly offer programs for uninsured or underinsured patients meeting income criteria.

Employer advocacy: Some self-insured employers have added GLP-1 coverage after employees advocated for it, particularly when presenting the long-term cost savings of treating obesity versus managing its complications.

The Affordability Crisis

The fundamental problem is that medications costing pennies to manufacture are priced at over $12,000/year. This pricing reflects U.S. pharmaceutical market dynamics, not manufacturing costs. In countries with drug price negotiation, the same medications cost a fraction of the U.S. price. Until policy changes address this — through Medicare negotiation, importation, or competition — individual navigation of the current system remains necessary.

Maintaining results through proper nutrition and exercise maximizes the value of whatever treatment duration you can afford.